Mariarosaria Napolitano

Dr. Mariarosaria Napolitano


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
EBElena Bravo
Elena Bravo
SPSimonetta Palleschi
Simonetta Palleschi
PAPatricia Aspichueta
Patricia Aspichueta
XBXabier Buqué
Xabier Buqué
RRRossi Rossi
Rossi Rossi
KBKathleen Botham
Kathleen Botham
Hyperhomocysteinemia (HHcy) causes increased oxidative stress and is an independent risk factor for cardiovascular disease. Oxidative stress is now believed to be a major contributory factor in the development of non alcoholic fatty liver disease, the most common liver disorder worldwide. In this study, the changes which occur in homocysteine (Hcy) metabolism in high fat-diet induced non alcoholic fatty liver disease (NAFLD) in rats were investigated. After feeding rats a standard low fat diet (control) or a high fat diet (57% metabolisable energy as fat) for 18 weeks, the concentration of homocysteine in the plasma was significantly raised while that of cysteine was lowered in the high fat as compared to the control diet fed animals. The hepatic activities of cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGS), the enzymes responsible for the breakdown of homocysteine to cysteine via the transsulphuration pathway in the liver, were also significantly reduced in the high fat-fed group. These results indicate that high fat diet-induced NAFLD in rats is associated with increased plasma Hcy levels caused by down-regulation of hepatic CBS and CGL activity. Thus, HHcy occurs at an early stage in high fat diet-induced NAFLD and is likely to contribute to the increased risk of cardiovascular disease associated with the condition.

28 September 2006 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SASouliman Amrani
Souliman Amrani
HHHicham Harnafi
Hicham Harnafi
NBNour El Houda Bouanani
Nour El Houda Bouanani
MAMohammed Aziz
Mohammed Aziz
HCHana Serghini Caid
Hana Serghini Caid
EBElena Bravo
Elena Bravo

2 May 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CRCarmela Rozera
Carmela Rozera
GCGiancarlo Antonini Cappellini
Giancarlo Antonini Cappellini
GDGiuseppina D’agostino
Giuseppina D’agostino
LSLaura Santodonato
Laura Santodonato
LCLuciano Castiello
Luciano Castiello
ICImerio Capone
Imerio Capone
Advanced melanoma patients have an extremely poor long term prognosis and are in strong need of new therapies. The recently developed targeted therapies have resulted in a marked antitumor effect, but most responses are partial and some degree of toxicity remain the major concerns. Dendritic cells play a key role in the activation of the immune system and have been typically used as ex vivo antigen-loaded cell drugs for cancer immunotherapy. Another approach consists in intratumoral injection of unloaded DCs that can exploit the uptake of a wider array of tumor-specific and individual unique antigens. However, intratumoral immunization requires DCs endowed at the same time with properties typically belonging to both immature and mature DCs (i.e. antigen uptake and T cell priming). DCs generated in presence of interferon-alpha (IFN-DCs), due to their features of partially mature DCs, capable of efficiently up-taking, processing and cross-presenting antigens to T cells, could successfully carry out this task. Combining intratumoral immunization with tumor-destructing therapies can induce antigen release in situ, facilitating the injected DCs in triggering an antitumor immune response. We tested in a phase I clinical study in advanced melanoma a chemo-immunotherapy approach based on unloaded IFN-DCs injected intratumorally one day after administration of dacarbazine. Primary endpoint of the study was treatment safety and tolerability. Secondary endpoints were immune and clinical responses of patients. Six patients were enrolled, and only three completed the treatment. The chemo-immunotherapy was well tolerated with no major side effects. Three patients showed temporary disease stabilization and two of them showed induction of T cells specific for tyrosinase, NY-ESO-1 and gp100. Of interest, one patient showing a remarkable long-term disease stabilization kept showing presence of tyrosinase specific T cells in PBMC and high infiltration of memory T cells in the tumor lesion at 21 months. We tested a chemo-immunotherapeutic approach based on IFN-DCs injected intratumorally one day after DTIC in advanced melanoma. The treatment was well tolerated, and clinical and immunological responses, including development of vitiligo, were observed, therefore warranting additional clinical studies aimed at evaluating efficacy of this approach. Trial Registration Number not publicly available due to EudraCT regulations: https://www.clinicaltrialsregister.eu/doc/EU_CTR_FAQ.pdf

1 November 2009 in Nutrition
Verified
Journal Article
Closed access
GSGhada M. Safwat
Ghada M. Safwat
SPStefania Pisanò
Stefania Pisanò
EDEmanuela D'AMore
Emanuela D'AMore
GBGiorgio Borioni
Giorgio Borioni
MNMariarosaria Napolitano
Mariarosaria Napolitano
EBElena Bravo
Elena Bravo

1 December 2007 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MNMariarosaria Napolitano
Mariarosaria Napolitano
CPClara De Pascale
Clara De Pascale
CWCaroline Wheeler-Jones
Caroline Wheeler-Jones
KBKathleen Botham
Kathleen Botham
EBElena Bravo
Elena Bravo
The effect of lycopene on macrophage foam cell formation induced by modified low-density lipoprotein (LDL) was studied. Human monocyte-derived macrophages (HMDM) were incubated with lycopene in the presence or absence of native LDL (nLDL) or LDL modified by oxidation (oxLDL), aggregation (aggLDL), or acetylation (acLDL). The cholesterol content, lipid synthesis, scavenger receptor activity, and the secretion of inflammatory [interleukin (IL)-1β and tumor necrosis factor (TNF)-α] and anti-inflammatory (IL-10) cytokines was determined. Lycopene was found to decrease the synthesis of cholesterol ester in incubations without LDL or with oxLDL while triacylglycerol synthesis was reduced in the presence of oxLDL and aggLDL. Scavenger receptor activity as assessed by the uptake of acLDL was decreased by ∼30% by lycopene. In addition, lycopene inhibited IL-10 secretion by up to 74% regardless of the presence of nLDL or aggLDL but did not affect IL-1β or TNF-α release. Lycopene also reduced the relative abundance of mRNA transcripts for scavenger receptor A (SR-A) in THP-1 macrophages treated with aggLDL. These findings suggest that lycopene may reduce macrophage foam cell formation induced by modified LDL by decreasing lipid synthesis and downregulating the activity and expression of SR-A. However, these effects are accompanied by impaired secretion of the anti-inflammatory cytokine IL-10, suggesting that lycopene may also exert a concomitant proinflammatory effect.

14 March 2003 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
MNMariarosaria Napolitano
Mariarosaria Napolitano
MAMichael Avella
Michael Avella
KBKathleen Botham
Kathleen Botham
EBElena Bravo
Elena Bravo